Czech startup Kardi Ai raises €5.3 million for heart monitoring expansion
Germany is an immediate priority as the company plans further market entries and develops predictive models that still need clinical validation and regulatory approval.
Czech medical technology startup Kardi Ai has secured €5.3 million in Series A financing, with German investor Callisto Health leading the round. The company said the money would support expansion in Europe and Asia, as well as development of technology intended to predict heart rhythm disorders.
Other investors included Garage Angels, DEPO Ventures, Purple Ventures and BrightCap Ventures. Česká spořitelna and Slovenská sporiteľňa also participated through Seed Starter.
Kardi Ai combines a chest-worn fitness strap containing an electrocardiogram (ECG) sensor with a mobile app and AI analysis. It is designed to record heart rhythms over extended periods during daily activities, helping doctors assess possible irregularities. The system supports medical decisions rather than making diagnoses.
Germany is among the company's immediate expansion priorities following pilot projects. Kardi Ai already operates in Poland, Romania and Bulgaria, and says it works with more than 20 physicians in Slovakia, most of them cardiologists.
The company says regulatory approvals are in place to support planned launches in India and the United Arab Emirates. It is still completing Singapore's medical device approval process. In the Czech Republic, Kardi Ai says it collaborates with more than 70 hospitals and has more than 6,000 users.
Alongside its expansion, Kardi Ai plans to build models that use repeated ECG measurements to estimate arrhythmia risk before an episode occurs. These remain in development and must undergo clinical validation and obtain regulatory approval before they can be used in medical practice.
